Anna M. Wu
YOU?
Author Swipe
View article: 309 Combining radiopharmaceutical therapy with CAR T cells to overcome the heterogeneous immunosuppressive prostate tumor microenvironment
309 Combining radiopharmaceutical therapy with CAR T cells to overcome the heterogeneous immunosuppressive prostate tumor microenvironment Open
View article: 957 Modulation of the tumor immune microenvironment by low dose antibody-based radiopharmaceutical therapy (RPT) and direct visualization of RPT analog microdistribution by imaging mass cytometry
957 Modulation of the tumor immune microenvironment by low dose antibody-based radiopharmaceutical therapy (RPT) and direct visualization of RPT analog microdistribution by imaging mass cytometry Open
View article: Reengineered Anti-CD4 Cys-diabody Variants for 89Zr-immunoPET of CD4+ T Cells in Immunocompetent Mice
Reengineered Anti-CD4 Cys-diabody Variants for 89Zr-immunoPET of CD4+ T Cells in Immunocompetent Mice Open
Purpose CD4 + T cells (T helper and T reg) play an important role in the immune system and are influential in autoimmune diseases (e.g., rheumatoid arthritis, inflammatory bowel disease) and cancer (antitumor immunity). Non-invasive, whole…
View article: Radiation-resistant Ti/BN coatings: insights from 171 days exposure to space radiation and atomic oxygen in low orbit
Radiation-resistant Ti/BN coatings: insights from 171 days exposure to space radiation and atomic oxygen in low orbit Open
Atmospheric Plasma Spray (APS) and Vacuum Plasma Spray (VPS) techniques were used to develop Ti/2 vol.% hBN coatings, for extreme space environments and tested aboard the International Space Station as part of the MISSE-17 (Materials Inter…
View article: 89Zr-anti-CD8 immunoPET visualizes heterogeneous intratumoral CD8+ immune responses to treatment with radiation and anti-CTLA4 in a preclinical syngeneic breast cancer model
89Zr-anti-CD8 immunoPET visualizes heterogeneous intratumoral CD8+ immune responses to treatment with radiation and anti-CTLA4 in a preclinical syngeneic breast cancer model Open
Anti-CD8 immunoPET facilitates non-invasive, whole-body visualization of immune responses, and syngeneic preclinical models are a crucial tool for studying tumor infiltration of T cells in response to cancer therapies. This study character…
View article: NLRP10 Cleaves Oxidized DNA inhibited by OGG1 inhibitors: A Newly Identified Role in DNA Damage Processing and Senescence Regulation
NLRP10 Cleaves Oxidized DNA inhibited by OGG1 inhibitors: A Newly Identified Role in DNA Damage Processing and Senescence Regulation Open
SUMMARY Mitochondrial DNA (mtDNA) release into the cytosol is a critical event in innate immune activation, often acting as a damage-associated molecular pattern (DAMP) that triggers inflammasome assembly. Here, we demonstrate that NLRP3 p…
View article: First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy
First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy Open
Purpose Prostate-specific membrane antigen (PSMA) is increasingly used to image prostate cancer in clinical practice. We sought to develop and test a humanised PSMA minibody IAB2M conjugated to the fluorophore IRDye 800CW-NHS ester in men …
View article: Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma
Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma Open
Peripheral T-cell lymphomas (PTCLs) have a poor prognosis with current treatments. High-dose chemotherapy followed by autologous hematopoietic cell transplant (AHCT) is used as a consolidation strategy after achieving clinical remission wi…
View article: Figure S4 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S4 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S4. DFO-conjugated anti-EMP2 mAb characteristics. A. Analysis of the various anti-EMP2−DFO conjugates using polyacrylamide gel electrophoresis (PAGE) showing changes in the migration of the intact antibody. B. Analysis of the various anti-…
View article: Figure S3 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S3 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S3. EMP2 expression in cancer cell lines. A. Based on public repositories, upregulation of EMP2 occurs in breast, brain, and ovarian cancers, while downregulation is predicted in hematopoietic cancers. B, C. Flow cytometry studies using a …
View article: Figure S4 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S4 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S4. DFO-conjugated anti-EMP2 mAb characteristics. A. Analysis of the various anti-EMP2−DFO conjugates using polyacrylamide gel electrophoresis (PAGE) showing changes in the migration of the intact antibody. B. Analysis of the various anti-…
View article: Figure S1 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S1 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S1. Summary of human EMP2 expression. A. HPA-RNAseq data depicting EMP2 mRNA expression in normal tissues. The image is reproduced from (https:www.ncbi.nlm.nih.gov/gene/2013). B. Immunohistochemical staining of representative human tissues…
View article: Data from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Data from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
Epithelial membrane protein-2 (EMP2) is upregulated in a number of tumors and therefore remains a promising target for mAb-based therapy. In the current study, image-guided therapy for an anti-EMP2 mAb was evaluated by PET in both syngenei…
View article: Supplementary Data from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Supplementary Data from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
Supplemental Figure Legends
View article: Figure S1 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S1 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S1. Summary of human EMP2 expression. A. HPA-RNAseq data depicting EMP2 mRNA expression in normal tissues. The image is reproduced from (https:www.ncbi.nlm.nih.gov/gene/2013). B. Immunohistochemical staining of representative human tissues…
View article: Supplemental Tables from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Supplemental Tables from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
Supplemental Tables
View article: Data from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Data from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
Epithelial membrane protein-2 (EMP2) is upregulated in a number of tumors and therefore remains a promising target for mAb-based therapy. In the current study, image-guided therapy for an anti-EMP2 mAb was evaluated by PET in both syngenei…
View article: Figure S3 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S3 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S3. EMP2 expression in cancer cell lines. A. Based on public repositories, upregulation of EMP2 occurs in breast, brain, and ovarian cancers, while downregulation is predicted in hematopoietic cancers. B, C. Flow cytometry studies using a …
View article: Figure S5 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S5 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S5. Binding characteristics. Analysis of the various anti-EMP2−DFO conjugates using flow cytometry binding on U87MG/EMP2FLuc. N=3, with the EC50 determined using nonlinear regression. B. 10:1 DFO:mAb ratio retains specific binding to EMP2 …
View article: Supplemental Tables from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Supplemental Tables from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
Supplemental Tables
View article: Figure S5 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S5 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S5. Binding characteristics. Analysis of the various anti-EMP2−DFO conjugates using flow cytometry binding on U87MG/EMP2FLuc. N=3, with the EC50 determined using nonlinear regression. B. 10:1 DFO:mAb ratio retains specific binding to EMP2 …
View article: Figure S7 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S7 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S7. ImmunoPET imaging with 89Zr-DFO- anti-EMP2 mAb of U87MG/EMP2Fluc or sham injected nude mouse in an intracranial model. All mice received the same surgical procedures, but they were injected with either U87MG/EMP2Fluc cells or saline (s…
View article: Supplementary Data from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Supplementary Data from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
Supplemental Figure Legends
View article: Figure S2 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S2 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S2. EMP2 expression in the mouse. Expression of EMP2 was determined by immunohistochemical staining in C57B/6 WT or EMP2 knockout mice with representative images shown from select tissue. Magnification: 400X.
View article: Figure S7 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S7 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S7. ImmunoPET imaging with 89Zr-DFO- anti-EMP2 mAb of U87MG/EMP2Fluc or sham injected nude mouse in an intracranial model. All mice received the same surgical procedures, but they were injected with either U87MG/EMP2Fluc cells or saline (s…
View article: Figure S2 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S2 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S2. EMP2 expression in the mouse. Expression of EMP2 was determined by immunohistochemical staining in C57B/6 WT or EMP2 knockout mice with representative images shown from select tissue. Magnification: 400X.
View article: Figure S6 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S6 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S6. Pharmacokinetics and in vivo tumor expression. A. Tumor growth of syngeneic 4T1FLuc, CT26, and Panc02 tumors over the imaging period. B. Correlation of the average EMP2 histological score and mean %ID/cc in 4T1FLuc, CT26 and Panc02 tum…
View article: Figure S6 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S6 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S6. Pharmacokinetics and in vivo tumor expression. A. Tumor growth of syngeneic 4T1FLuc, CT26, and Panc02 tumors over the imaging period. B. Correlation of the average EMP2 histological score and mean %ID/cc in 4T1FLuc, CT26 and Panc02 tum…
View article: Integrating Artificial Intelligence and PET Imaging for Drug Discovery: A Paradigm Shift in Immunotherapy
Integrating Artificial Intelligence and PET Imaging for Drug Discovery: A Paradigm Shift in Immunotherapy Open
The integration of artificial intelligence (AI) and positron emission tomography (PET) imaging has the potential to become a powerful tool in drug discovery. This review aims to provide an overview of the current state of research and high…
View article: Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy
Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy Open
CAR (chimeric antigen receptor) T cell therapy has shown clinical success in treating hematological malignancies, but its treatment of solid tumors has been limited. One major challenge is on-target, off-tumor toxicity, where CAR T cells a…